A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis

Psoriasis Area and Severity Index (PASI)

Change from Baseline in PASI score

Time frame: Baseline to Weeks 2, 4 and 8

Psoriasis Area and Severity Index (PASI) -50

Percent of patients who achieved PASI-50

Time frame: Baseline to Week 12

Psoriasis Area and Severity Index (PASI) -75

Percent of patients who achieved PASI-75

Time frame: Baseline to Week 12

Physician's Global Assessment (PGA)

Change from Baseline in PGA score

Time frame: Baseline to Weeks 4, 8 and 12

Physician's Global Assessment (PGA)

Percent of patients who achieve PGA score of 0 or 1

Time frame: Week 12

Psoriasis-Affected Body Surface Area (BSA)

Change from Baseline in Psoriasis-Affected BSA

Time frame: Baseline to Weeks 4, 8 and 12

Safety measure through incidence of treatment-emergent adverse events (TEAEs)

The number of patients experiencing TEAEs and number of individual TEAEs will be summarized among treatment arms, by system organ class (SOC) and PT. TEAEs will also be summarized among treatment arms, by severity and by relationship to study drug.